Published Online: Wednesday, August 1, 2007

The FDA will form a new advisory committee of outside specialists to advise the agency on how to inform the public about the risks and benefits of medicines and medical devices. The Risk Communication Advisory Committee will:

  • Help the FDA better understand the communication needs and priorities of the general public
  • Advise the FDA on the development of strategic plans to communicate product risks and benefits
  • Make recommendations to the FDA based on current research about crafting risk and benefit messages, as well as how to effectively communicate specific product information to vulnerable audiences

The committee "will bring together a broad range of experts and views to help improve the FDA's communication of the science-based information about product risks and benefits that the public needs to make informed decisions."

Latest Articles
The FDA has approved betamethasone dipropionate spray, 0.05%, as a treatment for mild to moderate plaque psoriasis in patients aged 18 years and older.
Medication errors injure thousands of patients annually, and while mistakes occur with all medication classes, those involving antiretroviral therapies are particularly troublesome.
Acute respiratory infections such as the common cold are often accompanied by cough and congestion caused by mucus hypersecretion.
Poor medication adherence is responsible for unnecessary illness, hospitalizations, disability, and premature death, particularly among patients with chronic diseases.
Latest Issues